Investors / United States / Versant Ventures
Versant Ventures
Venture capital · San Francisco, CA, United States · North America
Versant Ventures is a venture capital firm that has been investing since 1999 and reports $5.5B under management. It operates Discovery Engines, in-house teams of scientists working in laboratory facilities to launch new biotechnology companies with academic founders.
Invests inHealthcare & Biotech
In its own wordsbiotechlife scienceshealthcarecompany creationacademic partnerships
Your fit with Versant Ventures
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsVersant Ventures lists 59 checked portfolio companies on its own site and is named in 10 funding rounds, 4 of them as lead. Its most frequent entry is Series A, 71% of the companies with a known first round. Its largest themes are Healthcare & Biotech (90%), AI & Machine Learning (3%) and Robotics & Hardware (2%). 69% of its companies are based in United States. It invests most often alongside RA Capital, NEA and Avoro Capital Advisors.
Counts come from funding rounds that name Versant Ventures, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Round figures show recent activity, not Versant Ventures' whole history. Rounds on record name 8 companies; its own site lists 59. Funding rounds are complete from mid-2025, so counts and the yearly trend undercount a firm that invested before then. The portfolio, themes and places come from its own site and are not affected.
Entry stage
share of companies by the stage of its first roundVersant Ventures does not state its stages on its site, so only what it does is shown.
Show as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 71% |
| Series B | 0% |
| Growth | 29% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 1 | 0 |
| '23 | 1 | 1 |
| '24 | 2 | 1 |
| '25 | 4 | 2 |
| '26 | 2 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 88th | 59 companies |
| Recent activity | 76th | 3 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 73th | 8% of companies confirmed by a round |
| Sector focus | 95th | 90% in its largest sector |
| Reach | 84th | 6 countries |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| RA Capital | 8 |
| NEA | 7 |
| Avoro Capital Advisors | 5 |
| Inception Therapeutics | 5 |
| 5AM Ventures | 4 |
| Andreessen Horowitz | 4 |
| Boxer Capital | 4 |
| Casdin Capital | 4 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers5695%
- No longer answers00%
- Points to another company35%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 90% | 15% |
| AI & Machine Learning | 3% | 18% |
| Robotics & Hardware | 2% | 1% |
| Industrial & Manufacturing | 2% | 7% |
| Space & Defense | 2% | 3% |
| Enterprise Software | 2% | 8% |
Co-investor network
who it backs companies with, and who they back togetherCompare Versant Ventures head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with Versant Ventures| Date | Company | Stage |
|---|---|---|
| 19 Oct 2026 | Series C+ | |
| 15 Jul 2026 | Series A | |
| 13 Nov 2025 | Series B | |
| 16 Sept 2025 | Series A Led | |
| 16 Sept 2025 | Series A Led | |
| 13 Jun 2024 | Series B | |
| 13 Jun 2024 | Series A Led | |
| 1 Nov 2023 | Series A Led |
Round details for Versant Ventures
Amounts, full round histories and every co-investor in Versant Ventures' rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
59 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| 858 Therapeutics is a clinical-stage biotechnology company developing therapies designed to target tumor dependencies in DNA damage response pathways. | Healthcare & Biotech | Portfolio page | ||
| Adaxion Therapeutics is advancing biologics deimmunized with their ADAx platform to overcome immunogenicity limitations in biologic therapies | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Akero Therapeutics is pioneering novel therapies to transform the lives of people living with serious metabolic diseases | Healthcare & Biotech | Portfolio page | ||
| Aligos Therapeutics develops therapies for liver and viral diseases | Healthcare & Biotech | Portfolio page | ||
| Allrock Bio develops therapies for cardio-pulmonary diseases. | Healthcare & Biotech | Sept 2025Series A | Page + round | |
| AlterG produces and sells anti-gravity treadmills for physical rehabilitation and training | Healthcare & Biotech | Portfolio page | ||
| Antag Therapeutics is pioneering a new class of therapies for people living with obesity, diabetes and overweight. | Healthcare & Biotech | Portfolio page | ||
| Aprea Therapeutics is a biopharmaceutical company focused on developing novel DDR targeted cancer therapeutics. | Healthcare & Biotech | Portfolio page | ||
| Belharra Therapeutics develops therapeutics by illuminating novel binding pockets on drug targets across the proteome | Healthcare & Biotech | Portfolio page | ||
| BlueRock Therapeutics creates next-generation medicines for patients in need by harnessing the power of cell therapy | Healthcare & Biotech | Portfolio page | ||
| Borealis Biosciences develops RNA medicines to treat kidney diseases | Healthcare & Biotech | Portfolio page | ||
| Bright Peak Therapeutics is developing novel designer immunotherapies for the treatment of cancer using its proprietary protein engineering capabilities. | Healthcare & Biotech | Portfolio page | ||
| Capsida Biotherapeutics is developing next generation, targeted genetic medicines for rare and more common neurological and ocular diseases across all ages. | Healthcare & Biotech | Portfolio page | ||
| Century Therapeutics develops allogeneic, iPSC-derived cell therapies to treat autoimmune diseases and cancer. | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Cimeio Therapeutics develops curative therapies for patients with hematologic disorders using cell-shielding technology and paired immunotherapies | Healthcare & Biotech | Portfolio page | ||
| Portfolio page | ||||
| Crinetics Pharmaceuticals is a company that develops and commercializes therapies, particularly for endocrine diseases. | Healthcare & Biotech | Portfolio page | ||
| CRISPR Therapeutics is developing gene-based medicines for serious diseases | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- versantventures.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 9 Feb 2022
- Companies checked
- 59
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get Versant Ventures' profile as data
Pull Versant Ventures' portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/versantventures.com
# also
GET /v1/firms/versantventures.com/portfolio
GET /v1/firms/versantventures.com/coinvestors
GET /v1/firms/versantventures.com/news